You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
Pulmonology
ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?
Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.
MD, MAS
Stephanie Christenson +2 more
Learning objectives
Understand the shared and unique disease burden in COPD with type 2 inflammation and moderate-to-severe asthma
Identify the role of type 2 inflammation in the pathophysiology of moderate-to-severe asthma and COPD with type 2 inflammation
Differentiate between the clinical manifestations of type 2 inflammation in moderate-to-severe asthma and COPD with type 2 inflammation using real-world patient cases
Description
Join Dr. Nicola Hanania, Dr. Stephanie Christenson, and Dr. Mario Castro as they explore the shared and unique pathophysiological features of type 2 inflammation--driven asthma and COPD and the real-world impact on patients.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
All rights reserved. MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025
All Rights Reserved.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.